Tectonic Therapeutic Management
Management criteria checks 2/4
Tectonic Therapeutic's CEO is Alise Reicin, appointed in Aug 2020, has a tenure of 4.75 years. total yearly compensation is $5.90M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 1.56% of the company’s shares, worth $5.75M. The average tenure of the management team and the board of directors is 3.8 years and 5 years respectively.
Key information
Alise Reicin
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 10.27% |
| CEO tenure | 4.8yrs |
| CEO ownership | 1.6% |
| Management average tenure | 3.8yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
Apr 23Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Feb 05Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Jan 30We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth
Jan 10
Tectonic Therapeutic: Waiting For A Pullback
Dec 30Tectonic Therapeutic: Interesting CV Disease Drug Developer
Oct 20Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation
Sep 22Tectonic Therapeutic: Analyzing Its Post-Merger Valuation And Prospects
Aug 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$59m |
| Dec 31 2024 | US$6m | US$606k | -US$58m |
| Sep 30 2024 | n/a | n/a | -US$53m |
| Jun 30 2024 | n/a | n/a | -US$46m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$932k | US$575k | -US$43m |
Compensation vs Market: Alise's total compensation ($USD5.90M) is above average for companies of similar size in the US market ($USD2.75M).
Compensation vs Earnings: Alise's compensation has increased whilst the company is unprofitable.
CEO
Alise Reicin (63 yo)
4.8yrs
Tenure
US$5,900,979
Compensation
Dr. Alise S. Reicin, MD, PhD, serves as Member of Strategic Advisory Board at SCTbio a.s. (formerly known as Sotio a.s.). since November 2021. She serves on the board of directors of Sana Biotherapeutics a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$5.90m | 1.56% $ 5.8m | |
| Co-Founder & Independent Director | 5.9yrs | US$186.33k | 31.28% $ 115.4m | |
| Chief Financial Officer | less than a year | US$2.48m | 0.025% $ 91.2k | |
| Chief Medical Officer | 3.8yrs | US$1.84m | 0.34% $ 1.3m | |
| Chief Scientific Officer | 2.9yrs | no data | 0.076% $ 280.3k | |
| Senior Vice President of People & Culture | 2.8yrs | no data | no data | |
| Chief Development Officer | no data | no data | no data | |
| Chief Business Officer | 4.2yrs | no data | 0.025% $ 92.9k | |
| Senior Vice President of Antibody Engineering & Protein Sciences | no data | no data | no data |
3.8yrs
Average Tenure
56yo
Average Age
Experienced Management: TECX's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$5.90m | 1.56% $ 5.8m | |
| Co-Founder & Independent Director | 5.9yrs | US$186.33k | 31.28% $ 115.4m | |
| Independent Chairman of the Board | 5.7yrs | US$203.08k | 0.11% $ 400.4k | |
| Independent Director | less than a year | US$189.83k | 0.00089% $ 3.3k | |
| Independent Director | 5.3yrs | US$187.33k | 0.016% $ 60.0k | |
| Independent Director | 3.8yrs | US$188.58k | no data |
5.0yrs
Average Tenure
63yo
Average Age
Experienced Board: TECX's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 14:52 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tectonic Therapeutic, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Risinger | Leerink Partners LLC |
| Uy Ear | Mizuho Securities USA LLC |
| Yasmeen Rahimi | Piper Sandler Companies |